ETON Eton Pharmaceuticals: Company Short-Term Debts

Public company logo of Eton Pharmaceuticals (ETON)

This price chart illustrates the debt dynamics of Eton Pharmaceuticals (ETON), whose strategy is based on merging proprietary research with the acquisition of rights to niche medications to expand its distribution network. The current figure is 0.01. Management is implementing a lean approach to developing treatments for rare pediatric pathologies, utilizing licensing to mitigate risks. Eton Pharmaceuticals (ETON) creates innovative therapies through close collaboration with specialized scientists and physicians.

ETON (Eton Pharmaceuticals, Inc.) Company Short-Term Debts history from 07/04/2022 to 11/01/2026

Metric breakdowns and analytics for Eton Corp (ETON)

- stock price and consensus target price:
Stock Price Eton Pharmaceuticals, Inc.|ETON - Consensus Target
- company stock capitalization data:
Market Capitalization Eton Pharmaceuticals, Inc.|ETON - Company Buyout Price
- business book valuation details:
Book Value per Share Eton Pharmaceuticals|ETON - Book Capitalization|Market Value to Book Value Ratio etonpharma.com|ETON - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Eton Pharmaceuticals|ETON - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Eton Pharmaceuticals|ETON - Company Aggregate Indebtedness|Debts to Book Capitalization Eton Pharmaceuticals, Inc.|ETON - Long-Term Debt|Company Short-Term Debts Eton Pharmaceuticals|Quick Liquidity Indicator etonpharma.com
- net income and valuation multiples indicators:
ETON - Final Profit
Summary company analysis:Eton Pharmaceuticals, Inc. (ETON)
Manufactured products of etonpharma.com

For Eton Pharmaceuticals (ETON), current borrowings reflect the dynamics of liabilities maturing within one year. This indicator measures balance sheet liquidity, capturing the volume of short-term credit pressure on capital. The value 0.01 demonstrates the issuer's current debt load. A decrease in this metric confirms financial recovery, which is critical when bringing niche drugs to market. Stable flows from rare diseases allow for efficient debt management without excessive R&D expenditures.

Main competitors

Vertex - Company Short-Term Debts|Alnylam Pharmaceuticals, Inc. (ALNY) - Company Current Liabilities|INSM: Company Short-Term Debts|UTHR - Short-Term Debt Volume|BMRN (BioMarin Pharmaceutical) - Company Short-Term Debts|Company Short-Term Debts bridgebio.com|Company Short-Term Debt BGM Group Ltd (BGM)|Company Short-Term Debt COGT (Cogent Biosciences Inc)|Company Short-Term Debts XERS (Xeris Biopharma Inc)|Short-Term Debt Volume Keros Corp (KROS)|ARCT: Company Current Liabilities|Current Liabilities KMDA|FULC: Company Short-Term Debts|Short-Term Debt Abeona Therapeutics Inc. (ABEO)|MREO (Mereo BioPharma Group) - Company Short-Term Debts|Company Short-Term Indebtedness PLX (Protalix BioTherapeutics, Inc)|Company Current Liabilities PLRX (Pliant Therapeutics)|APLT (Applied Therapeutics Inc.) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Rein Therapeutics RNTX|GELS (Gelteq Ltd) - Current Liabilities|Aytu Therapeutics - Company Short-Term Debts|Company Short-Term Loans and Borrowings CMMB (Chemomab Therapeutics)|SRXH: Company Short-Term Debts|Polyrizon (PLRZ) - Company Short-Term Debts|Company Short-Term Debt Aeterna Zentaris Inc|CYTH: Company Short-Term Loans and Borrowings|Company Short-Term Debt Inozyme Pharma, Inc. (INZY)|Company Current Liabilities Reneo Pharmaceuticals, Inc RPHM|Company Short-Term Debts CSCI (COSCIENS Biopharma Inc.)